Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Head and Neck Squamous Cell Carcinoma
Clinical trial register · China

Head and Neck Squamous Cell Carcinoma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19224 matching records held by the registry are in this view. Synced 11 Nov 2026, 03:17 UTC
19224
Studies in scope
all four open statuses
11811
Recruiting now
open to new participants
2030
Lead sponsors
across recruiting studies
Top sites
Shanghai 18 Guangzhou 13 Chengdu 11 Beijing 9 Wuhan 6
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sichuan Baili Pharmaceutical Co., Ltd.7 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University7 West China Hospital5 Fudan University4 Beijing Tongren Hospital3
Site location
Shanghai18 Guangzhou13 Chengdu11 Beijing9 Wuhan6
All 34 locations
Target enrolment
to

Head and Neck Squamous Cell Carcinoma trials in China

58 of 19224 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma
NCT07827872Oral Squamous Cell Carcinoma (OSCC), Head and Neck Squamous Cell Carcinoma, Early-stage Oral Cancer
DrugsSintilimab·Nab-paclitaxel·Carboplatin
caohaotian
Phase 3
300
Guangzhou
2026-10-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
86
Hebei
2026-09-02
Recruiting
AbbVie
Phase 2
150
2026-09-01
Recruiting
Online Sharing for Head & Neck Cancer Support
NCT07766226Head and Neck Squamous Cell Carcinoma
West China Hospital
Not applicable
120
Chengdu
2026-08-28
Not yet open
Dongguan People's Hospital
Phase 2
65
Dongguan
2026-08-10
Recruiting
West China Hospital
Phase 2
90
Chengdu
2026-07-20
Recruiting
Lepu Biopharma Co., Ltd.
Phase 2
80
Beijing, Fuzhou, Guangzhou, Shantou, Nanning, Shijiazhuang, Wuhan, Changsha
2026-07-06
Recruiting
West China Hospital
Phase 2
9
Chengdu
2026-06-29
Recruiting
Clinical Study of CFH Protein Via Ice Microneedles for Radiation-Induced Skin Fibrosis
NCT07567235Radiation-Induced Skin Fibrosis, Head and Neck Squamous Cell Carcinoma
West China Hospital
Phase 1
9
Chengdu
2026-06-15
Active, closed
Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck Cancer
NCT07791602Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Cancer, HNSCC
DrugsTuoyi·Camrelizumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
180
Beijing, Harbin, Shenyang, Taiyuan, Tianjin
2026-06-12
Not yet open
Neoadjuvant Radio-immunotherapy Versus Immunotherapy Alone for Locally Advanced HNSCC
NCT07554768Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma
DrugAdebrelimab
Chen Chunyan
Phase 2
36
Guangzhou
2026-05-01
Not yet open
Sun Yat-sen University
Phase 2
42
Foshan, Guangzhou, Qingyuan, Shantou, Shenzhen, Zhanjiang, Ganzhou
2026-05
Recruiting
Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07601737Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Head & Neck Cancer, Neoadjuvant Therapy
DrugsAlbumin-Bound Paclitaxel /nab-Paclitaxel·Nimotuzumab·Tislelizumab·Docetaxel
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2
182
Shanghai
2026-04-20
Recruiting
H101 Plus TACE for r/m HNSCC
NCT07398664Head and Neck Squamous Cell Carcinoma, Oncolytic Virus, TACE
DrugH101
West China Hospital
Phase 2
20
Chengdu
2026-03-02
Not yet open
Neoadjuvant Becotatug Vedotin Plus Pucotenlimab and Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07393477Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC
Sir Run Run Shaw Hospital
Phase 2
30
Hangzhou
2026-02
Recruiting
First in Human Study of SIM0610 in Solid Tumors
NCT07348211Advanced Solid Tumours, Non-Small Cell Lung Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
260
Chongqing, Harbin, Shenyang, Jinan, Shanghai
2026-01-19
Recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 2
110
Shanghai
2025-12-12
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
16
Chengdu
2025-12-10
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
22
Chengdu
2025-12-10
Recruiting
Fudan University
Phase 1/2
68
Shanghai
2025-05-13
Recruiting
PDO Based Drug Sensitive Test in R/M HNSCC
NCT06686342Head and Neck Squamous Cell Carcinoma, Patient Derived Organoid, Drug Sensitive Test in Vitro
Huashan Hospital
Observational
100
Shanghai
2025-03-26
Not yet open
Reconstruction of Cervical Lymphatic System During Head and Neck Squamous Cell Carcinoma Surgery
NCT06815705Head and Neck Squamous Cell Carcinoma, Lymphedema, Secondary, Neck Lymph Dissection, Vascularized Lymph Node Transplantation
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
23
Guangzhou
2025-03-20
Active, closed
Gilead Sciences
Phase 2
39
Chengdu, Hangzhou, Nanning, Shanghai, Wuhan
2025-02-18
Not yet open
Fudan University
Phase 2
80
Shanghai
2025-02-10
Not yet open
The First Affiliated Hospital with Nanjing Medical University
Phase 2
45
Nanjing
2024-12-03
Recruiting
Beijing Tongren Hospital
Phase 2
50
Beijing
2024-12-01
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
48
Shanghai
2024-11-07
Recruiting
Akeso
Phase 3
510
Wuhan, Chengdu
2024-10-30
Recruiting
Shanghai Institute Of Biological Products
Phase 2
81
Shanghai
2024-09-27
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
302
Guanzhou
2024-09-01
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
100
Guangzhou
2024-08-13
Recruiting
Fudan University
Phase 2
52
Shanghai
2024-07-03
Recruiting
Lei Liu
Phase 2
90
Chengdu
2024-07-01
Recruiting
Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC
NCT06494943Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
DrugsCis-platinum·Sintilimab·Paclitaxel
Fudan University
Phase 1/2
27
Shanghai
2024-06-26
Active, closed
Lyvgen Biopharma Holdings Limited
Phase 2
64
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Zhengzhou, Wuhan, Changsha
2024-06-21
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
46
Shanghai
2024-06-07
By invitation
Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
NCT06690216Glioblastoma (GBM), Head and Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer
Man Hu
Phase 1/2
100
Jinan
2024-03-30
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
154
Guangzhou
2024-03-25
Recruiting
Hansoh BioMedical R&D Company
Phase 2
170
Hefei, Beijing, Fuzhou, Guangzhou, Zhuhai, Nanning, Harbin, Zhengzhou
2023-12-18
Recruiting
Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC
NCT06170710Head and Neck Squamous Cell Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
173
Beijing
2023-12-01
Recruiting
HRYZ-T101 Injection for HPV18 Positive Solid Tumor
NCT05952947Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Carcinoma of Vagina, Carcinoma of Penis
DrugsFludarabine·Cyclophosphamide
HRYZ Biotech Co.
Phase 1
32
Shanghai
2023-11-01
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
186
Shanghai
2023-10-20
Not yet open
Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC
NCT05993858Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy
DrugCetuximab
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
33
Wuhan
2023-10-20
Active, closed
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2
72
Shanghai
2023-10-17
Recruiting
Beijing Tongren Hospital
Phase 2
100
Beijing
2023-10-01
Not yet open
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
30
Guangzhou
2023-09-01
Recruiting
Beijing Tongren Hospital
Phase 3
272
Beijing
2023-05-01
Recruiting
Fifth Affiliated Hospital, Sun Yat-Sen University
Not applicable
23
Zhuhai
2023-04-10
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
100
Guangzhou
2023-03-01
Active, closed
Toripalimab-based Neoadjuvant Therapy in LA-HNSCC
NCT05522985Head and Neck Squamous Cell Carcinoma, Neoadjuvant Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2
122
Tianjin
2022-09-02
Recruiting
Zhejiang Provincial People's Hospital
Phase 2
80
Qingdao, Hangzhou, Ningbo, Tianjin, Wenzhou
2022-09-01
Active, closed
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase 2
25
Zhuhai, Dongguan
2022-03-09
Recruiting
Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC
NCT05272696Head and Neck Squamous Cell Carcinoma
Guangdong Provincial People's Hospital
Phase 2
86
Guangzhou
2022-03-01
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
45
Guilin, Guiyang, Wuhan, Changsha, Shanghai, Chengdu, Hangzhou
2021-12-22
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
11
Guilin, Guiyang, Shanghai
2021-10-20
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
57
Guangzhou
2021-07-08
Active, closed
Suzhou Junde Biotechnology Co., Ltd
Phase 1/2
108
Shanghai
2021-05-26
Recruiting
Yuankai Shi
Phase 2
150
Beijing
2021-04-30
Rows per page Showing 1–58 of 58
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 November 2026. https://priyalifescience.com/clinical-trials-china/condition/head-and-neck-squamous-cell-carcinoma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,224 studies in total at the last sync on 11 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 58 of those studies listing the condition Head and Neck Squamous Cell Carcinoma.

How many Head and Neck Squamous Cell Carcinoma trials are recruiting in China?

37 of the 58 studies on this page are recruiting new participants as of the 11 Nov 2026, 03:17 UTC sync. A further 10 have not yet opened recruitment, 10 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Head and Neck Squamous Cell Carcinoma), 58 studies
PhaseStudiesRecruitingShare
Phase 2402369%
Phase 1558.6%
Phase 1/2426.9%
Not applicable325.2%
Observational335.2%
Phase 3325.2%

Most active sponsors

Lead sponsors with the most studies (Head and Neck Squamous Cell Carcinoma)
Lead sponsorStudiesRecruiting
Sichuan Baili Pharmaceutical Co., Ltd.74
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University75
West China Hospital55
Fudan University43
Beijing Tongren Hospital33
Cancer Institute and Hospital, Chinese Academy of Medical Sciences32
Fifth Affiliated Hospital, Sun Yat-Sen University21
AbbVie11
Akeso11
caohaotian10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.